MetaCap

Cryo-Cell International (CCEL) vs DaVita (DVA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

DaVita (DVA) has outperformed Cryo-Cell International (CCEL) over the past year, gaining 33.9% versus a gain of 1.5%. Over five years, DVA leads with a +65.5% price change compared with -66.3% for CCEL. DaVita is the larger company by market cap ($10.13 billion vs $33.5 million), about 302.7 times the size.

On valuation, DaVita trades at a lower forward P/E (9.5x vs 207.5x for Cryo-Cell International). DaVita converts more of its revenue into profit, with a net margin of 5.5% versus -7.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CCEL+1.47%DVA+33.91%
+107%+36%-36%
Nov 21, 20251 yearNov 20, 2026
CCEL-66.12%DVA+61.76%
+152%+32%-87%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CCEL versus DVA key metrics
MetricCCELDVA
Share price$4.15$161.03
Market cap$33.46M$10.13B
1-day change0.00%+3.00%
YTD return+20.64%+41.74%
1-year return+1.47%+33.91%
5-year return-66.34%+65.52%
P/E ratio (TTM)—12.19
Forward P/E207.509.52
EPS (TTM)$-0.24$13.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$31.57M$13.64B
Revenue growth (YoY)-1.31%+6.46%
Net income (latest FY)$-2.43M$746.80M
Gross margin76.63%—
Operating margin1.53%14.98%
Net margin-7.70%5.47%
52-week high$5.45$247.49
52-week low$2.72$101.00
Distance from 52-week high-23.85%-34.93%
Analyst consensus—buy
Avg. price target upside—+38.04%
Average volume13.02K738.70K
Shares outstanding8.06M62.90M
Employees7278,000
SectorHealth CareHealth Care
IndustryMisc Health and Biotechnology ServicesMisc Health and Biotechnology Services

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DaVita is about 302.7 times larger than Cryo-Cell International by market value ($10.13B vs $33.46M).
  • DVA has outperformed CCEL by 32.4 percentage points over the past year.
  • DaVita is more profitable, keeping 5.5 cents of every revenue dollar as net income versus -7.7 cents for Cryo-Cell International.
  • DaVita grew revenue faster in its latest fiscal year (+6.46% vs -1.31%).

About Cryo-Cell International

CCEL stock →

Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States.

Health Care · Misc Health and Biotechnology Services · 72 employees

About DaVita

DVA stock →

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States.

Health Care · Misc Health and Biotechnology Services · 78,000 employees

CCEL vs DVA FAQ

Which is bigger, Cryo-Cell International or DaVita?

DaVita (DVA) is larger, with a market capitalization of $10.13B compared with $33.46M for Cryo-Cell International (CCEL).

Which stock has performed better over the past year, CCEL or DVA?

DVA returned +33.91% over the past 12 months, compared with +1.47% for CCEL (price return, excluding dividends). Past performance does not predict future results.

Are Cryo-Cell International and DaVita in the same industry?

Yes. Both are classified in the Misc Health and Biotechnology Services industry within the Health Care sector.

More comparisons